There are currently four ongoing trials on ambroxol effectiveness in PD and DLB patients without GBA mutations, which could provide us an answer for this issue (NCT05778617, NCT02941822, NCT04405596, NCT04588285). This evidence concerns the gene GBA1 and Parkinson disease.